Depletion or inhibition of NAMPT has been shown to increase ROS in models of NSCLC (40), leukemia (43, 97), prostate cancer (19), breast cancer (61), glioblastoma (102), CRC (112), and others (85). This evidence concerns the gene NAMPT and Familial prostate cancer.